First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China.

ABSTRACT:

Background

The primary analysis of the CAP-BRAIN trial has shown preliminary antitumour activity and safety of first-line camrelizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC) and brain metastases (BMs). Here, we report the final efficacy analysis of the CAP-BRAIN study following an additional 3-years of follow-up from the data cut-off date of the primary analysis, along with updated safety data.

Methods

In this multicentre, open-label, single-arm, phase 2 trial conducted at seven hospitals in China, 45 adult patients with treatment-naive metastatic non-squamous NSCLC and asymptomatic BMs (or intracranial hypertension symptom controlled with dehydration therapy) were treated with four cycles of camrelizumab (200 mg) plus pem

SUBMITTER: Hou X 

PROVIDER: S-EPMC12661349 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature